# Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors

> **NCT04765462** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Malignant Solid Tumours

## Interventions

- **BIOLOGICAL:** Allogeneic γδ T cells

## Key facts

- **NCT ID:** NCT04765462
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04765462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04765462, "Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04765462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*